Back to Journals » OncoTargets and Therapy » Volume 11

Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma

Authors Li X, Li X, Fang X, Yuan Y

Received 19 October 2017

Accepted for publication 8 May 2018

Published 16 July 2018 Volume 2018:11 Pages 4047—4050

DOI https://doi.org/10.2147/OTT.S154567

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Geoffrey Pietersz


Xiaofen Li,1,2,* Xia Li,3,* Xuefeng Fang,1 Ying Yuan1

1
Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; 2Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; 3Department of Operation Room, Zhejiang Province People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China

*These authors contributed equally to this work

Abstract:
To date, there is no standard third-line therapy for EGFR- and ALK-negative lung squamous cell carcinoma (SCC). Apatinib, an oral small-molecule VEGFR-2 inhibitor, has shown good therapeutic effect and safety in chemotherapy-refractory gastric cancer, but its efficacy in lung SCC is not determined. In this report, we present a 69-year-old Chinese man with locally advanced EGFR- and ALK-negative lung SCC, who received apatinib after failure of 2 treatment regimens. After 4 months of apatinib therapy, chest computed tomography scan showed a large cavity in the lung tumor, while there was minimal change in tumor size. The patient had quite a long progression-free survival time of over 17 months and tolerated apatinib very well. Apatinib provides an additional option for salvage treatment of lung SCC without driver gene mutations, but further large-scale clinical studies are still warranted.

Keywords: apatinib, lung squamous cell carcinoma, efficacy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]